In Japan, a commercially developed Hp preparation (haptoglobin I.V. 2000 units; JB, Japan Blood Products Organization, Tokyo, Japan) was approved for the treatment of hemoglobinemia and hemoglobinuria induced by hemolysis in 1985. Here, HP is linked to hemoglobinuria.